Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nicole LamannaMark A Weiss

Abstract

Purine analogs and alkylators are important agents for treating chronic lymphocytic leukemia (CLL). Early studies combining fludarabine and chlorambucil were abandoned owing to increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin appears to be the least myelosuppressive. We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination. We treated 46 patients with either previously treated CLL (32 patients) or other low-grade B-cell neoplasms (14 patients). Patients received pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2 (PCR). All drugs were administered on the same day (rituximab omitted from cycle 1), and patients received six cycles at 3-week intervals. Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylactically. The median age was 62 years (range, 30 to 80 years). The median number of prior regimens was two (range, one to seven). For CLL patients, there were 24 responses (75%), including eight complete responses (25%). In fludarabine-refractory...Continue Reading

References

Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingK B McCredie
Apr 2, 1987·The New England Journal of Medicine·A S SpiersM J O'Connell
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R O DillmanO R McIntyre
Sep 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R GreverS P Balcerzak
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Juliusson, J Liliemark
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC A White
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Oct 6, 2001·Blood·M LeporrierUNKNOWN French Cooperative Group on Chronic Lymphocytic Leukemia
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vicki A MorrisonCharles A Schiffer
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A WeissDenise Horgan
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William WierdaMichael Keating
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian

❮ Previous
Next ❯

Citations

Apr 4, 2009·Targeted Oncology·Alfonso Quintás-Cardama, Susan O'Brien
Jan 27, 2009·Current Treatment Options in Oncology·Tahamtan AhmadiEdward Stadtmauer
Mar 16, 2013·Current Treatment Options in Oncology·Sanford Kempin
Dec 1, 2006·Current Hematologic Malignancy Reports·Stefan FaderlMichael J Keating
Apr 29, 2010·Current Hematologic Malignancy Reports·Nicole Lamanna
Jan 12, 2012·Current Hematologic Malignancy Reports·Nicole Lamanna
Aug 21, 2007·Current Oncology Reports·Asher A Chanan-Khan
Aug 19, 2008·Current Oncology Reports·Nicole Lamanna, Mark A Weiss
Jul 5, 2011·Advances in Therapy·Danelle F James, Thomas J Kipps
Sep 30, 2009·Nature Reviews. Clinical Oncology·Ashkan EmadiRobert A Brodsky
Jul 7, 2010·Nature Reviews. Clinical Oncology·Constantine S Tam, Michael J Keating
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Nov 6, 2007·Cancer Biotherapy & Radiopharmaceuticals·Neil E KayMichael R Grever
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Feb 4, 2011·OncoTargets and Therapy·Alessandra TedeschiMarco Montillo
Jan 13, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Gillian M Keating
Nov 17, 2009·Drugs·Tadeusz RobakPawel Robak
Apr 19, 2011·Clinical Medicine Insights. Oncology·Chadi Nabhan, Neil E Kay
Jan 1, 2010·Clinical & Developmental Immunology·Giulia MottaAlessio Nencioni
Oct 30, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vicki A Morrison
Jul 19, 2005·Cancer Immunology, Immunotherapy : CII·Farhad Ravandi, Susan O'Brien
Feb 3, 2015·Leukemia & Lymphoma·Constantine S Tam, Stephan Stilgenbauer
Apr 7, 2010·Leukemia & Lymphoma·Myron S Czuczman, Stephanie A Gregory
Jun 16, 2010·Leukemia & Lymphoma·Apostolia-Maria Tsimberidou, Michael J Keating
Aug 8, 2013·Expert Review of Anticancer Therapy·Loretta J NastoupilChristopher R Flowers
Mar 1, 2012·Expert Opinion on Biological Therapy·Tadeusz Robak
Nov 1, 2007·Expert Opinion on Investigational Drugs·Mohamed A Kharfan-DabajaEdgardo S Santos
Aug 30, 2008·Expert Opinion on Drug Metabolism & Toxicology·Craig SauterMark A Weiss
Dec 22, 2012·Expert Opinion on Biological Therapy·Preetesh Jain, Susan O'Brien
Jun 22, 2013·Leukemia Research·Joshua Lukenbill, Matt Kalaycio
Apr 9, 2013·Hematology/oncology Clinics of North America·Deborah M Stephens, John C Byrd
Jul 14, 2010·Best Practice & Research. Clinical Haematology·Vicki A Morrison
Mar 31, 2010·Seminars in Hematology·Samantha M Jaglowski, John C Byrd

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.